Exploring High Growth Tech Stocks In November 2024

In This Article:

Global markets have recently experienced significant shifts, with U.S. stocks rallying to record highs following a Republican electoral sweep, leading to expectations of accelerated earnings growth and reduced regulatory burdens. Amidst these developments, the small-cap Russell 2000 Index has shown impressive gains, highlighting the potential opportunities within high-growth tech stocks as investors seek companies that can thrive under favorable economic policies and lower corporate taxes.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Material Group

20.45%

24.01%

★★★★★★

Yggdrazil Group

24.66%

85.53%

★★★★★★

eWeLLLtd

26.52%

27.53%

★★★★★★

Ascelia Pharma

76.15%

47.16%

★★★★★★

Medley

24.98%

30.36%

★★★★★★

Seojin SystemLtd

33.39%

49.13%

★★★★★★

Sarepta Therapeutics

23.89%

42.65%

★★★★★★

Mental Health TechnologiesLtd

27.88%

79.61%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

UTI

114.97%

134.60%

★★★★★★

Click here to see the full list of 1278 stocks from our High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Zealand Pharma

Simply Wall St Growth Rating: ★★★★★☆

Overview: Zealand Pharma A/S is a biotechnology company focused on discovering, developing, and commercializing peptide-based medicines in Denmark, with a market cap of DKK61.99 billion.

Operations: Zealand Pharma generates its revenue primarily from its biotechnology segment, amounting to DKK76.87 million. The company is engaged in the discovery, development, and commercialization of peptide-based medicines.

Zealand Pharma's recent trajectory illustrates a challenging phase, with a significant revenue drop to DKK 4.42 million in Q3 2024 from DKK 295.52 million the previous year and escalating losses, signaling intense development focus rather than market performance. This period of heavy investment in R&D is evident as the firm navigates regulatory hurdles, such as the FDA's response requiring further data for dasiglucagon’s application. Despite these setbacks, Zealand Pharma remains committed to innovation in biopharmaceuticals, aiming to transform treatment landscapes for metabolic and gastrointestinal diseases—a strategy that might redefine its growth path amid high industry expectations marked by a forecasted annual revenue increase of 50.1%.

CPSE:ZEAL Revenue and Expenses Breakdown as at Nov 2024
CPSE:ZEAL Revenue and Expenses Breakdown as at Nov 2024

Cowell e Holdings

Simply Wall St Growth Rating: ★★★★★★

Overview: Cowell e Holdings Inc. is an investment holding company that designs, develops, manufactures, and sells optical modules and systems integration products for smartphones and other mobile devices across several international markets, with a market cap of approximately HK$22.51 billion.